Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:chemical_compound
anticonvulsant |
| gptkbp:approvedBy |
gptkb:US_Food_and_Drug_Administration
gptkb:European_Medicines_Agency |
| gptkbp:ATCCode |
N03AX17
|
| gptkbp:brand |
Diacomit
|
| gptkbp:CASNumber |
49763-96-4
|
| gptkbp:discoveredBy |
Biocodex
|
| gptkbp:discoveredIn |
1978
|
| gptkbp:hasMolecularFormula |
C14H18O3
|
| gptkbp:hasSMILES |
CC(C1=CC=CC=C1O)(C2=CC=CC=C2O)CO
|
| https://www.w3.org/2000/01/rdf-schema#label |
stiripentol
|
| gptkbp:KEGGID |
gptkb:D08513
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
GABAergic modulation
inhibition of cytochrome P450 enzymes |
| gptkbp:PubChem_CID |
gptkb:CHEMBL1201202
5311 DB06149 |
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
loss of appetite weight loss insomnia drowsiness ataxia |
| gptkbp:UNII |
0C1XK1K4E3
|
| gptkbp:usedFor |
treatment of Dravet syndrome
|
| gptkbp:bfsParent |
gptkb:Dravet_syndrome
|
| gptkbp:bfsLayer |
7
|